BillionToOne, Inc.
Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $108.15 ($105.56–$110.09, $2.16M total) across 11 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
BillionToOne (BLLN) reported a peer-reviewed study showing its Northstar Response ctDNA assay had 94% concordance with a tumor-informed test, matching clinical ground truth in all discordant cases. The study supports BLLN's tumor-agnostic monitoring approach, according to the company.
BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BLLN (BillionToOne, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent BLLN coverage spans insider activity, technology and financial news.
In the last 30 days, BLLN insiders filed 48 SEC Form 4 transactions — no purchases and 48 sales ($15.5M). The most active reporter was Lynch Thomas P., See Remarks, with 17 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale of $2.16M may signal negative sentiment for BLLN.
Positive validation may boost investor confidence and drive short‑term buying pressure.
Positive clinical data may boost confidence in BLLN's assay platform and drive short‑term buying interest.
The insider sale may signal lack of confidence and could pressure the stock.
Significant insider sell may signal negative sentiment, potentially pressuring the stock short-term.
AlphAI scores every news story that mentions BLLN with an AI model for sentiment and relevance, and aggregates insider trades from BillionToOne, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $108.15 ($105.56–$110.09, $2.16M total) across 11 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readBillionToOne (BLLN) reported a peer-reviewed study showing its Northstar Response ctDNA assay had 94% concordance with a tumor-informed test, matching clinical ground truth in all discordant cases. The study supports BLLN's tumor-agnostic monitoring approach, according to the company.
1 min readBillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.
2 min readAtay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at $120.64 ($1.01M total) on 2026-09-28 under a Rule 10b5-1 trading plan.
1 min readLynch Thomas P. (See Remarks) sold 35,112 shares of BillionToOne, Inc. (BLLN) at an average of $110.33 ($110.29–$110.36, $3.87M total) across 4 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min readBillionToOne (BLLN) CEO Oguzhan Atay sold 30,331 shares for $3M on Sept 14, 2026, per SEC filing. The sale included cash-less option exercises and shares from his spouse's account, executed under a pre-planned trading plan. Atay retains 501,962 vested options and his spouse holds 157,168 shares. BLLN reported $109.4M Q2 2026 revenue, up 64% YoY, and forecasts $450M-$465M for full-year 2026.
2 min readAtay Oguzhan (Chairman and CEO) sold 5,332 indirectly-held shares of BillionToOne, Inc. (BLLN) at $98.00 ($0.52M total) across 2 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readAtay Oguzhan (Chairman and CEO) sold 24,999 shares of BillionToOne, Inc. (BLLN) at an average of $100.32 ($98.63–$101.49, $2.51M total) across 8 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readTsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $98.77 ($97.54–$100.00, $1.98M total) across 2 trades on 2026-09-09 under a Rule 10b5-1 trading plan.
1 min readLynch Thomas P. (See Remarks) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $99.99 ($96.47–$101.41, $2.00M total) across 13 trades on 2026-09-08 under a Rule 10b5-1 trading plan.
1 min read
